{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:26:32Z","timestamp":1791491192982,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1C1C1009815"],"award-info":[{"award-number":["NRF-2021R1C1C1009815"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2021IP0047"],"award-info":[{"award-number":["2021IP0047"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["20004927"],"award-info":[{"award-number":["20004927"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HR21C0198"],"award-info":[{"award-number":["HR21C0198"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background\n<\/jats:title>\n                <jats:p>The purpose of this study was to stratify patients with rheumatoid arthritis (RA) according to the trend of disease activity by trajectory-based clustering and to identify contributing factors for treatment response to biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) according to trajectory groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed the data from a nationwide RA cohort from the Korean College of Rheumatology Biologics and Targeted Therapy registry. Patients treated with second-line biologic and targeted synthetic DMARDs were included. Trajectory modeling for clustering was used to group the disease activity trend. The contributing factors using the machine learning model of SHAP (SHapley Additive exPlanations) values for each trajectory were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The trends in the disease activity of 688 RA patients were clustered into 4 groups: rapid decrease and stable disease activity (group 1, <jats:italic>n<\/jats:italic>\u2009=\u2009319), rapid decrease followed by an increase (group 2, <jats:italic>n<\/jats:italic>\u2009=\u200936), slow and continued decrease (group 3, <jats:italic>n<\/jats:italic>\u2009=\u2009290), and no decrease in disease activity (group 4, <jats:italic>n<\/jats:italic>\u2009=\u200943). SHAP plots indicated that the most important features of group 2 compared to group 1 were the baseline erythrocyte sedimentation rate (ESR), prednisolone dose, and disease activity score with 28-joint assessment (DAS28) (SHAP value 0.308, 0.157, and 0.103, respectively). The most important features of group 3 compared to group 1 were the baseline ESR, DAS28, and estimated glomerular filtration rate (eGFR) (SHAP value 0.175, 0.164, 0.042, respectively). The most important features of group 4 compared to group 1 were the baseline DAS28, ESR, and blood urea nitrogen (BUN) (SHAP value 0.387, 0.153, 0.144, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The trajectory-based approach was useful for clustering the treatment response of biologic and targeted synthetic DMARDs in patients with RA. In addition, baseline DAS28, ESR, prednisolone dose, eGFR, and BUN were important contributing factors for 4-year trajectories.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02918-3","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T07:03:39Z","timestamp":1665731019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"24","author":[{"given":"Bon San","family":"Koo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongho","family":"Eun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Keun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Seon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"9430","key":"2918_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263\u20139.","journal-title":"Lancet"},{"issue":"2","key":"2918_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/annrheumdis-2017-211871","volume":"77","author":"A Kavanaugh","year":"2018","unstructured":"Kavanaugh A, van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, Chen S, Guerette B, Kupper H, Smolen JS. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann Rheum Dis. 2018;77(2):289\u201392.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2918_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","volume":"22","author":"CS Lau","year":"2019","unstructured":"Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22(3):357\u201375.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2918_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2918_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2918_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-017-1293-1","volume":"19","author":"M Grabner","year":"2017","unstructured":"Grabner M, Boytsov NN, Huang Q, Zhang X, Yan T, Curtis JR. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. Arthritis Res Ther. 2017;19(1):92.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"2918_CR7","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1007\/s10067-020-05087-3","volume":"39","author":"F Navarro","year":"2020","unstructured":"Navarro F, Martinez-Sesmero JM, Balsa A, Peral C, Montoro M, Valderrama M, Gomez S, de Andres-Nogales F, Casado MA, Oyaguez I. Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol. 2020;39(10):2919\u201330.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"2918_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jbspin.2018.03.018","volume":"86","author":"T Lequerre","year":"2019","unstructured":"Lequerre T, Rottenberg P, Derambure C, Cosette P, Vittecoq O. Predictors of treatment response in rheumatoid arthritis. Joint Bone Spine. 2019;86(2):151\u20138.","journal-title":"Joint Bone Spine"},{"issue":"5","key":"2918_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","volume":"55","author":"BV Cuppen","year":"2016","unstructured":"Cuppen BV, Welsing PM, Sprengers JJ, Bijlsma JW, Marijnissen AC, van Laar JM, Lafeber FP, Nair SC. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford). 2016;55(5):826\u201339.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"2918_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/acr.20188","volume":"62","author":"W Katchamart","year":"2010","unstructured":"Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken). 2010;62(8):1128\u201343.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"2918_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","volume":"92","author":"CA Wijbrandts","year":"2017","unstructured":"Wijbrandts CA, Tak PP. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc. 2017;92(7):1129\u201343.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2918_CR12","doi-asserted-by":"publisher","first-page":"e0135327","DOI":"10.1371\/journal.pone.0135327","volume":"10","author":"C Barnabe","year":"2015","unstructured":"Barnabe C, Sun Y, Boire G, Hitchon CA, Haraoui B, Thorne JC, Tin D, van der Heijde D, Curtis JR, Jamal S, et al. Heterogeneous disease trajectories explain variable radiographic, function and quality of life outcomes in the Canadian Early Arthritis Cohort (CATCH). PLoS ONE. 2015;10(8):e0135327.","journal-title":"PLoS ONE"},{"issue":"1","key":"2918_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009742.2020.1774646","volume":"50","author":"M Leu Agelii","year":"2021","unstructured":"Leu Agelii M, Andersson M, Jones BL, Sjowall C, Kastbom A, Hafstrom I, Forslind K, Gjertsson I. Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome. Scand J Rheumatol. 2021;50(1):1\u201310.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"2918_CR14","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1093\/rheumatology\/ket253","volume":"52","author":"S Norton","year":"2013","unstructured":"Norton S, Sacker A, Dixey J, Done J, Williams P, Young A, Early Rheumatoid Arthritis S. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. Rheumatology (Oxford). 2013;52(11):2016\u201324.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2918_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.22175","volume":"66","author":"L Siemons","year":"2014","unstructured":"Siemons L, Ten Klooster PM, Vonkeman HE, Glas CA, Van de Laar M. Distinct trajectories of disease activity over the first year in early rheumatoid arthritis patients following a treat-to-target strategy. Arthritis Care Res (Hoboken). 2014;66(4):625\u201330.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"2918_CR16","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/1756-185X.13184","volume":"20","author":"N Wabe","year":"2017","unstructured":"Wabe N, Wojciechowski J, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Proudman S, Wiese MD. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. Int J Rheum Dis. 2017;20(10):1447\u201356.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2918_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/acr.24709","volume":"74","author":"VP Bykerk","year":"2022","unstructured":"Bykerk VP, Lee EB, van Vollenhoven R, Gruben DC, Fallon L, Woolcott JC, Keystone E. Identification of distinct disease activity trajectories in methotrexate-naive patients with rheumatoid arthritis receiving tofacitinib over twenty-four months. Arthritis Care Res (Hoboken). 2022;74(1):131\u201341.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2918_CR18","doi-asserted-by":"crossref","first-page":"1759720X2110439","DOI":"10.1177\/1759720X211043977","volume":"13","author":"Consortium R-M","year":"2021","unstructured":"Consortium R-M. Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study. Ther Adv Musculoskelet Dis. 2021;13:1759720X211043977.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"2918_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.semarthrit.2014.05.003","volume":"44","author":"S Norton","year":"2014","unstructured":"Norton S, Fu B, Scott DL, Deighton C, Symmons DP, Wailoo AJ, Tosh J, Lunt M, Davies R, Young A, et al. Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts. Semin Arthritis Rheum. 2014;44(2):131\u201344.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2918_CR20","doi-asserted-by":"publisher","first-page":"e0215999","DOI":"10.1371\/journal.pone.0215999","volume":"14","author":"Y Pan","year":"2019","unstructured":"Pan Y, Norton S, Gwinnutt JM, Kearsley-Fleet L, Symmons DPM, Lunt M, Young A, Consortium B-RCC, Hyrich KL, Verstappen SMM. Not all moderate disease is the same - identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. PLoS One. 2019;14(5):e0215999.","journal-title":"PLoS One"},{"key":"2918_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/annrheumdis-2014-eular.3505","volume":"73","author":"K Shin","year":"2014","unstructured":"Shin K, Choi SJ, Kwak S-K, Park Y-B, Sung Y-K, Choi C-B, Jeon CH, Lee J, Nam EJ, Kim S-K, et al. AB1066 Korean Biologics Registry of Patients with Systemic Rheumatic Disease (KOBIO): a nationwide registry to assess adverse events associated with biologic treatment in Korea. Ann Rheum Dis. 2014;73:1153\u20134.","journal-title":"Ann Rheum Dis"},{"key":"2918_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109\u201338.","journal-title":"Annu Rev Clin Psychol"},{"key":"2918_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1145\/2939672.2939785","volume-title":"Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","author":"T Chen","year":"2016","unstructured":"Chen T, Guestrin C. XGBoost a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. San Francisco: Association for Computing Machinery; 2016. p. 785\u201394."},{"key":"2918_CR24","first-page":"4768","volume":"30","author":"SM Lundberg","year":"2017","unstructured":"Lundberg SM, Lee S-I. A unified approach to interpreting model predictions:\u00a0Proceedings of the 31st International Conference on Neural Information Processing Systems December 2017. Adv Neural Inform Process Syst. 2017;30:4768\u201377.","journal-title":"Adv Neural Inform Process Syst"},{"issue":"1","key":"2918_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/ard.2010.135376","volume":"70","author":"JD Isaacs","year":"2011","unstructured":"Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis. 2011;70(1):4.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2918_CR26","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/rheumatology\/ker300","volume":"51","author":"PP Tak","year":"2012","unstructured":"Tak PP. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford). 2012;51(4):600\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2918_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-021-02567-y","volume":"23","author":"BS Koo","year":"2021","unstructured":"Koo BS, Eun S, Shin K, Yoon H, Hong C, Kim D-H, Hong S, Kim Y-G, Lee C-K, Yoo B, et al. Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics. Arthritis Res Ther. 2021;23(1):178.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2918_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrd.2016.21","volume":"15","author":"K Chaudhari","year":"2016","unstructured":"Chaudhari K, Rizvi S, Syed BA. Rheumatoid arthritis: current and future trends. Nat Rev Drug Discovery. 2016;15(5):305\u20136.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1233","key":"2918_CR29","doi-asserted-by":"publisher","first-page":"680043","DOI":"10.3389\/fphar.2021.680043","volume":"12","author":"S Shams","year":"2021","unstructured":"Shams S, Martinez JM, Dawson JRD, Flores J, Gabriel M, Garcia G, Guevara A, Murray K, Pacifici N, Vargas MV, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol. 2021;12(1233):680043.","journal-title":"Front Pharmacol"},{"issue":"4","key":"2918_CR30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/annrheumdis-2012-202709","volume":"73","author":"B Moller","year":"2014","unstructured":"Moller B, Scherer A, Forger F, Villiger PM, Finckh A, Swiss Clinical Quality Management Program for Rheumatic D. Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rheum Dis. 2014;73(4):691\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 7A","key":"2918_CR31","doi-asserted-by":"publisher","first-page":"50S","DOI":"10.1016\/j.amjmed.2003.12.012","volume":"116","author":"A Wilson","year":"2004","unstructured":"Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):50S-57S.","journal-title":"Am J Med"},{"issue":"7","key":"2918_CR32","doi-asserted-by":"publisher","first-page":"e68975","DOI":"10.1371\/journal.pone.0068975","volume":"8","author":"YJ Park","year":"2013","unstructured":"Park YJ, Cho CS, Emery P, Kim WU. LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study. PLoS ONE. 2013;8(7):e68975.","journal-title":"PLoS ONE"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02918-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T07:05:19Z","timestamp":1665731119000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02918-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2918"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02918-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"11 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval of the KOBIO registry was obtained from the institutional review boards of all 38 participating institutions, including the Institutional Review Board of Inje University Seoul Paik Hospital (PAIK 2018\u201311-005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}